A Study to Learn How Safe the Study Treatment BAY2701250 is, How it Affects the Body and How it Moves Into, Through and Out of the Body in Healthy Male Participants When a Single Amount is Given as an Injection Into the Vein (Intravenous Infusion) or Under the Skin (Subcutaneous Injection)

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 15, 2023

Primary Completion Date

May 20, 2025

Study Completion Date

May 20, 2025

Conditions

Pulmonary Hypertension Due to Left Heart Disease

Interventions

DRUG

BAY2701250 IV

Single does, intravenous infusion

DRUG

Placebo IV

Matching placebo for BAY2701250 IV

DRUG

BAY2701250 SC

Single dose, subcutaneous injection will be administered into abdominal subcutaneous fat tissue

DRUG

Placebo SC

Matching placebo for BAY2701250 SC

Trial Locations (1)

NUVISAN GmbH Neu-Ulm, Neu-Ulm